SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following the FDA's approval of BYSANTI (milsaperidone) for Bipolar I Disorder and Schizophrenia, with market participants eagerly anticipating a significant re-rating of its valuation. The drug's New Chemical Entity (NCE) status and patent protection through 2044, combined with the potential of its GLP-1 nausea candidate, are fueling widespread community discussion about a possible near-term buyout.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending on expectations of record profits and a substantial share repurchase program announcement this week, fueled by robust demand across its civil aerospace, defense, and power systems segments, including significant SMR and AI data center opportunities. The community is highly bullish, anticipating continued strong growth and dismissing short-term fluctuations ahead of the upcoming earnings report and potential analyst upgrades.

Berachain

Berachain (BERA) is trending amid recent network upgrades like Bectra, new Proof-of-Liquidity reward vault approvals, and a notable crypto treasury initiative with Greenlane Holdings. The community is sharply divided, with bulls highlighting its growing TVL and unique PoL model for potential gains, while bears voice concerns over recent token unlocks and selling pressure.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Tango Therapeutics Inc

Tango Therapeutics is generating significant buzz due to promising Phase 1/2 clinical data for its TNG462 cancer therapy in MTAP-deleted cancers, alongside a substantial $225 million PIPE financing. The community is actively discussing the potential "best-in-class" status of its oncology pipeline, with some analysts raising price targets and speculation growing around future growth or acquisition, despite recent price fluctuations.

Moo Deng

MOODENG CRYPTO is trending amidst a significant surge in recent price action and high trading volume, fueling enthusiastic community speculation about its potential for explosive upward movement. Despite acknowledging its memecoin volatility, many are anticipating further gains, driven by its low market capitalization and the prospect of major exchange listings.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as community optimism grows around QNX's deepening integration into next-generation software-defined vehicles with key design wins like BMW's Neue Klasse and partnerships such as Alloy Kore with Vector, leading to expectations of accelerated revenue growth and strong Q3 earnings from its expanding automotive software portfolio.

Warner Music Group Corp. engages in the publishing and recording of music. It operates through the Recorded Music and Music Publishing segments. The Recorded Music segment is involved in the sale, marketing, distribution, and licensing of recorded music produced by the company's recording artists. The Music Publishing segment acts as a copyright owner and/or administrator of the musical compositions and generates revenues related to the exploitation of musical compositions. The company was founded on November 21, 2003 and is headquartered in New York, NY.

Warner Music Group Corp - Ordinary Shares - Class A

Warner Music Group is trending due to its new multi-year partnership with Spotify, focused on expanding fan experiences and monetization, alongside its inclusion in the S&P MidCap 400. The community is actively discussing these growth catalysts and recent analyst upgrades, though some express caution regarding artist cost pressures and existing leverage.

Lithium Argentina AG is a resource and materials company that engages in the production of lithium carbonate for lithium-ion batteries and electric vehicles. Its projects include: Cauchari-Olaroz and Pastos Grandes. The company was founded by Raymond Edward Flood, Jr. on November 27, 2007 and is headquartered in Zug, Switzerland.

Lithium Argentina AG

Lithium Argentina (LAR) is trending as lithium prices surge due to tightening supply and rising demand from various sectors, positioning the in-production miner to capitalize immediately. Investors are actively discussing LAR's significant production ramp-up, expansion plans with Ganfeng, and recent analyst upgrades, viewing it as a deeply undervalued play within the re-energized lithium sector.

Entegris, Inc. engages in the development, manufacture, and supply of specialty materials for the microelectronics industry. It operates through the following segments: Materials Solutions (MS), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The MS segment provides materials-based solutions, such as chemical mechanical planarization slurries and pads, deposition materials, process chemistries and gases, formulated cleans, etchants, and other specialty materials. The MC segment offers advanced solutions that improve customers’ yield, device reliability, and cost by filtering and purifying critical liquid chemistries and gases used in semiconductor manufacturing processes and other high-technology industries. The AMH segment develops solutions that improve customers’ yields by protecting critical materials during manufacturing, transportation, and storage, including products that monitor, protect, transport and deliver critical liquid chemistries, wafers, and other substrates for a broad set of applications in the semiconductor, life sciences, and other high-technology industries. The company was founded in 1966 and is headquartered in Billerica, MA.

Entegris Inc

Entegris is trending following a strong quarterly performance and an optimistic long-term outlook, propelled by growth in AI and advanced semiconductor manufacturing and reinforced by recent CHIPS Act funding. The community is actively discussing bullish sentiment and notable institutional accumulation, even with some analysts highlighting mixed near-term guidance.

BlackRock Institutional Trust Company N.A. - iShares China Large-Cap ETF

iShares China Large-Cap ETF

The iShares China Large-Cap ETF is a major discussion point, with community sentiment divided between optimism over a looming US-China trade truce and China's recent central bank actions to stimulate the economy, versus ongoing concerns about its deflationary pressures and property sector challenges. Many are watching for clear policy signals to confirm a sustainable breakout for deeply undervalued Chinese equities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).  In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

ALXN
Alexion Pharmaceuticals, Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ALXN News

ALXNAlexion Pharmaceuticals, Inc.